First Trust Nasdaq Pharmaceuticals ETF Rating → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free FTXH Stock Alerts $26.80 -0.09 (-0.33%) (As of 05/10/2024 06:55 PM ET) Add Compare Share Share RatingsStock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestSocial MediaStock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestSocial Media First Trust Nasdaq Pharmaceuticals ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.FTXH Aggregate RatingModerate Buy2.57Holdings in FTXH have an aggregate rating of Moderate Buy based on 640 analyst ratings issued in the past year covering 50 companies (99.9% of the portfolio).FTXH Aggregate Price Target$32.2620.38% UpsideHigh Prediction$40.69Average Prediction$32.26Low Prediction$24.52Holdings in FTXH have an aggregate price target of $32.26 and a range of $24.52 to $40.69 covering 50 companies (99.9% of the portfolio).FTXH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy7 Buy rating(s)Moderate Buy33 Moderate Buy rating(s)Hold9 Hold rating(s)Reduce0 Reduce rating(s)Sell1 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by First Trust Nasdaq Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 50 FTXH Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings7.78%PFEPfizer$28.53+1.9%5 of 5 stars2.40$35.86 25.7%157.45%MRKMerck & Co., Inc.$128.74-1.0%5 of 5 stars2.58$131.33 2.0%126.91%ABBVAbbVie$161.76+0.6%4 of 5 stars2.77$174.31 7.8%13Short Interest ↑6.87%JNJJohnson & Johnson$150.69+0.5%5 of 5 stars2.46$175.86 16.7%13Short Interest ↑Analyst Revision6.44%BMYBristol-Myers Squibb$45.24+0.7%5 of 5 stars2.11$60.00 32.6%19Short Interest ↓Analyst Revision4.22%AMGNAmgen$309.12-0.3%5 of 5 stars2.52$305.65 -1.1%213.91%UTHRUnited Therapeutics$266.39+0.8%5 of 5 stars2.90$308.78 15.9%10Insider Selling3.72%BIIBBiogen$223.59+0.9%5 of 5 stars2.65$288.46 29.0%26Positive News3.68%REGNRegeneron Pharmaceuticals$977.46+0.4%4 of 5 stars2.70$981.71 0.4%20Positive News3.62%LLYEli Lilly and Company$752.50-1.0%5 of 5 stars2.84$757.95 0.7%19Earnings ReportDividend AnnouncementShort Interest ↓3.54%VTRSViatris$11.33+1.5%1 of 5 stars1.33$11.00 -2.9%3Earnings ReportDividend Announcement3.54%VRTXVertex Pharmaceuticals$427.17+1.0%4 of 5 stars2.48$432.18 1.2%25Earnings ReportAnalyst Downgrade3.34%GILDGilead Sciences$66.88+1.4%5 of 5 stars2.39$83.69 25.1%18Analyst Revision3.28%CAHCardinal Health$98.94-0.6%5 of 5 stars2.50$107.00 8.1%12Dividend IncreaseAnalyst Downgrade3.13%ZTSZoetis$171.18+1.3%5 of 5 stars3.00$211.75 23.7%7Short Interest ↑3.02%JAZZJazz Pharmaceuticals$112.46+2.6%5 of 5 stars2.85$192.75 71.4%132.88%OGNOrganon & Co.$20.85+2.1%5 of 5 stars2.50$22.60 8.4%4Ex-Dividend2.03%CRLCharles River Laboratories International$226.96-0.5%5 of 5 stars2.64$253.55 11.7%11Earnings ReportAnalyst ForecastAnalyst Revision1.56%PRGOPerrigo$30.77+0.2%5 of 5 stars3.00$40.67 32.2%3Gap Down1.46%MEDPMedpace$392.60+0.6%5 of 5 stars2.80$443.00 12.8%5Insider SellingGap Down1.28%HALOHalozyme Therapeutics$43.76+1.4%5 of 5 stars2.83$53.14 21.4%60.96%INCYIncyte$57.33+8.0%5 of 5 stars2.47$74.93 30.7%17Short Interest ↑Gap Up0.93%ALKSAlkermes$24.49+1.8%5 of 5 stars2.50$35.38 44.4%10Positive News0.91%NBIXNeurocrine Biosciences$138.06+1.0%5 of 5 stars2.74$147.88 7.1%230.89%EXELExelixis$21.46+0.4%5 of 5 stars2.63$26.33 22.7%16Short Interest ↑0.82%PBHPrestige Consumer Healthcare$70.75+0.5%4 of 5 stars2.50$110.00 55.5%2Upcoming EarningsPositive News0.70%ELANElanco Animal Health$17.09+0.5%3 of 5 stars2.57$17.29 1.1%7Earnings ReportShort Interest ↓Analyst Revision0.59%BPMCBlueprint Medicines$107.18+0.4%1 of 5 stars2.50$100.31 -6.4%16Short Interest ↑0.59%ILMNIllumina$114.05+3.2%5 of 5 stars2.30$164.65 44.4%20Analyst UpgradeShort Interest ↓0.56%EXASExact Sciences$54.84+2.5%5 of 5 stars2.92$95.40 74.0%13Short Interest ↓Analyst Revision0.54%SRPTSarepta Therapeutics$130.99-0.6%4 of 5 stars2.79$160.60 22.6%140.52%KRYSKrystal Biotech$157.87+2.0%4 of 5 stars3.00$171.00 8.3%9Earnings ReportShort Interest ↑Analyst RevisionGap Down0.52%VKTXViking Therapeutics$73.06-0.8%5 of 5 stars3.00$112.25 53.6%100.52%RYTMRhythm Pharmaceuticals$39.85+1.8%3 of 5 stars2.83$54.33 36.3%6Earnings Report0.52%ROIVRoivant Sciences$11.14+0.1%3 of 5 stars2.90$16.90 51.7%10Positive News0.52%MRUSMerus$46.05+3.4%1 of 5 stars3.00$56.33 22.3%11Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage0.51%ITCIIntra-Cellular Therapies$66.26+2.0%5 of 5 stars2.90$90.17 36.1%10Earnings ReportAnalyst Revision0.50%BMRNBioMarin Pharmaceutical$81.37+0.4%5 of 5 stars2.63$107.50 32.1%19Short Interest ↑0.50%ACLXArcellx$50.04+0.6%3 of 5 stars3.00$78.20 56.3%12Earnings Report0.49%IDYAIDEAYA Biosciences$41.35+0.4%3 of 5 stars3.00$47.50 14.9%12Earnings ReportShort Interest ↑Analyst Revision0.49%TGTXTG Therapeutics$17.25+3.8%4 of 5 stars2.83$29.83 72.9%60.49%MLTXMoonLake Immunotherapeutics$42.50+3.9%3 of 5 stars2.75$74.46 75.2%12Earnings ReportAnalyst RevisionNews Coverage0.48%IONSIonis Pharmaceuticals$39.01-0.2%4 of 5 stars2.71$59.54 52.6%14Earnings ReportShort Interest ↓0.45%KYMRKymera Therapeutics$38.83+2.5%0 of 5 stars2.50$41.10 5.8%120.43%RAREUltragenyx Pharmaceutical$41.77+2.1%4 of 5 stars2.92$87.85 110.3%120.43%NUVLNuvalent$66.81+2.0%3 of 5 stars2.90$90.78 35.9%10Earnings ReportAnalyst Revision0.38%ACADACADIA Pharmaceuticals$15.35+0.7%4 of 5 stars2.75$28.94 88.5%16Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews Coverage0.37%ARVNArvinas$32.23+2.5%2 of 5 stars2.88$61.13 89.7%16Earnings ReportAnalyst Revision0.34%CRSPCRISPR Therapeutics$57.85+13.1%3 of 5 stars2.35$73.93 27.8%17Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage0.30%BEAMBeam Therapeutics$23.77+11.8%1 of 5 stars2.38$40.18 69.0%13Earnings ReportShort Interest ↑Analyst Revision This page (NASDAQ:FTXH) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersTrump is sounding the alarmPreserve GoldThis 1 Biotech Stock has been shocking the marketsHuge AlertsNext President (Not Trump. Not Biden.)The Freeport SocietyThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust Nasdaq Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
